Advertisement
Screener

Monopar Therapeutics Inc. (MNPR) Debt Securities, Available-for-sale

1.9 / 5 stars · 10/26 Roast Me

Monopar Therapeutics Inc. Debt Securities, Available-for-sale

Monopar Therapeutics Inc. (MNPR) had Debt Securities, Available-for-sale of $600.00 thousand as of 2023-03-31, per its 10-Q filed 2023-05-11.

Discontinued › Balance Sheet › Assets

us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2023-05-11

  • 2023-03-31: Debt Securities, Available-for-sale $600.00K.
  • 2022-12-31: Debt Securities, Available-for-sale $490.00K; Debt Securities, Available-for-sale as first filed $4.90M.
Period endDebt Securities, Available-for-saleDebt Securities, Available-for-sale as first filed
2023-03-31$600.00K
10-Q · filed 2023-05-11
2022-12-31$490.00K
10-Q · filed 2023-05-11
$4.90M
10-K · filed 2023-03-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Altimmune, Inc. (ALT)United States$0.593B-6.43
CorMedix Inc. (CRMD)United States$0.605B3.25
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
Neurogene Inc. (NGNE)$0.625B-4.46
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Indaptus Therapeutics, Inc. (INDP)United States$0.537B